Media stories about DarioHealth (NASDAQ:DRIO) have trended somewhat negative this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. DarioHealth earned a media sentiment score of -0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4612861728152 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several equities research analysts have recently commented on the company. ValuEngine raised DarioHealth from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Aegis reaffirmed a “buy” rating on shares of DarioHealth in a research note on Friday, December 8th.
DRIO stock traded up $0.02 during mid-day trading on Wednesday, reaching $1.50. The company had a trading volume of 35,145 shares, compared to its average volume of 65,374. DarioHealth has a 12-month low of $1.32 and a 12-month high of $4.65. The stock has a market cap of $16.16, a price-to-earnings ratio of -0.99 and a beta of -1.68.
DarioHealth (NASDAQ:DRIO) last posted its earnings results on Monday, March 19th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.95). DarioHealth had a negative net margin of 309.54% and a negative return on equity of 361.24%. The company had revenue of $1.58 million during the quarter. equities research analysts anticipate that DarioHealth will post -0.79 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/03/21/somewhat-critical-news-coverage-somewhat-unlikely-to-impact-dariohealth-drio-stock-price.html.
DarioHealth Company Profile
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.